Filing Flows › Starling Oncology (STLN) › Capital expenditures
Starling Oncology (STLN) capital expenditures by quarter
Starling Oncology's capital expenditures were $1.3M in Q3 2026 (third quarter 2026), +39% from Q2 2026. Over the last 3 quarters it ranged from $908K (Q2 2026) to $1.3M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.3M | +39% | — |
| Q2 2026 | $908K | -14% | — |
| Q4 2025 | $1.1M | — | — |
Q3 2026 at a glance
Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Starling Oncology's capital expenditures?
Starling Oncology's capital expenditures were $1.3M in Q3 2026 (third quarter 2026), +39% from Q2 2026.
How has Starling Oncology's capital expenditures changed?
Over the last 3 quarters it ranged from $908K (Q2 2026) to $1.3M (Q3 2026).